CompanyREGNNasdaqTarrytown, NY

Regeneron Pharmaceuticals

Regeneron develops monoclonal antibodies and bispecific antibodies for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

Stories only

SEC EDGAR ClinicalTrials.gov regeneron.com

8-KSep 30Latest SEC filing

Sep 30Latest story

September 2026

Regeneron registers prostate cancer bispecific trial; posts REGN5381 heart failure results

Sep 30Weekly roundup, 4 itemsamrecibart cenvacibartUpdated

Regeneron grants long-term PSUs to co-founders, forms new subsidiary

Sep 30PeopleRegeneron Pharmaceuticals

Regeneron registers two new trials: prion disease gene therapy and HS/obesity combo drug

Sep 22Weekly roundup, 2 itemsALN-6457 olatorepatide

Regeneron's EYLEA HD posts Phase 3b safety results; dupilumab keloid study completes

Sep 18Weekly roundup, 2 itemsaflibercept dupilumab

Regeneron registers two new cemiplimab trials in skin cancer and early lung cancer

Sep 9Weekly roundup, 2 itemscemiplimab-rwlc Regeneron Pharmaceuticals

August 2026

Sanofi's itepekimab COPD mechanism study AERIFY-3 posts results after 2025 completion

Aug 31Trial updateitepekimab Regeneron Pharmaceuticals

Regeneron lists vonsetamig as available under compassionate use program

Aug 21Trial updateRegeneron Pharmaceuticals vonsetamig

Regeneron registers Phase 1b trial of Factor XI/XII antibodies in dialysis patients

Aug 12Trial updateamrecibart cenvacibart

Regeneron registers Phase 1 REGN17235 trial and joins Maryland-led lung cancer study

Aug 7Weekly roundup, 2 itemscemiplimab-rwlc Regeneron Pharmaceuticals

July 2026

FDA approves REMS-related supplement for Lynozyfic (linvoseltamab-gcpt)

Jul 31Regulatory decisionlinvoseltamab-gcpt Regeneron Pharmaceuticals

Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial misses

Jul 30Quarterly updatecemdisiran fianlimab

Regeneron backs two new trials: cemiplimab in transplant patients, blood cancer genetics study

Jul 20Weekly roundup, 2 itemscemiplimab-rwlc Regeneron Pharmaceuticals

Regeneron registers Phase 3 PICC clot-prevention trial; Sanofi runs sarilumab study as collaborator

Jul 17Weekly roundup, 3 itemsamrecibart cenvacibart

FDA approves subcutaneous Sarclisa Escena with on-body injector for multiple myeloma

Jul 15Regulatory decisionisatuximab isatuximab-irfc

Regeneron's Phase 2 olatorepatide obesity trial recruiting across five U.S. sites

Jul 6Trial updateolatorepatide Regeneron Pharmaceuticals

Regeneron expects $127 million IPR&D charge in Q2 2026

Jul 6Quarterly updateRegeneron Pharmaceuticals

June 2026

Regeneron registers Phase 3 cat allergy trial and Phase 1/2 glaucoma antibody study

Jun 30Weekly roundup, 2 itemsfreneslerbart mevonlerbart

Pipeline by stage

Phase 3 primary completions, next 6 months

Feb 2027cenvacibartvenous thromboembolism (vte) · NCT07015905

Mar 2027cemiplimab-rwlcmelanoma · NCT06246916

Details

Headquarters: Tarrytown, NY
Incorporated: New York
Industry: Pharmaceutical Preparations
Formerly: REGENERON PHARMACEUTICALS INC (to 2019)
Also known as: Checkmate Pharmaceuticals, Decibel Therapeutics, REGENERON PHARMACEUTICALS, INC., REGN, RENGENERON PHARMACEUTICALS, INC.

How the company describes itself